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Abstract 
Diabetes mellitus is a serious public health issue, particularly in developing nations due to the cost associated with its 
management and its debilitating complications. Patients with diabetes mellitus type 1 are insulin-dependent due to 
complete loss of insulin producing beta cells in the pancreas and require a well-balanced regimen of insulin injections 
for life-time. The patients with diabetes mellitus type 2 also require insulin therapy in later stages of disease. In these 
patients insulin helps by correcting the insulin deficiency, however, the root cause of the disease still persists. 
Regenerative therapy is now offering solutions and hope to people with insulin-dependent diabetes. This paper gives 
an outline of the currently used methods in regenerative medicine that aim to re-establish the functional beta cells and 
restore the body’s original ability to regulate blood glucose levels. 
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1.0 INTRODUCTION 
Diabetes is a global public health problem that threatens the economy of all nations, particularly the 
developing nations. According to the International Diabetes Federation, at least 285 million people 
worldwide are affected by diabetes, and by the year 2030, the number is expected to reach 438 million. 
Nearly two-third of all diabetes cases occurs in low- and middle-income countries. (Zhang et al. 2010) 
Asia accounts for 60% of the world's diabetic population (Chan et al. 2009). The costs associated with the 
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management of diabetes are enormous. It was estimated that diabetes accounts for 12% of health 
expenditures globally, or at least $376 billion—a figure expected to hit $490 billion in 2030 (Zhang et al. 
2010). 
The current therapeutic approaches in the management of diabetes primarily aim to control high blood 
sugar level without addressing the primary cause of elevated blood sugar level. Considering the huge cost 
associated with the management of diabetes mellitus, it is now crucial to explore the newer technologies 
that may help in correcting the root cause of the disease. These approaches may benefit patients by 
eliminating the risk of long-term complications on one hand and saving on the cost associated with life-
long management on the other hand. In this paper we present a brief outline of the currently used 
technologies in regenerative medicine that aim to address the root cause of diabetes mellitus. 
Diabetes mellitus: Types and current management 
 Diabetes mellitus is of two types. The most common type of diabetes that generally has onset 
during adulthood is largely a lifestyle disease, and is known as diabetes mellitus type II. Genetic makeup 
also plays a role in development of diabetes mellitus type 2. At the onset, patients with type 2 diabetes 
have elevated blood sugar levels as the body’s sensitivity to insulin is reduced. Insulin is a hormone 
produced by the beta cells of pancreas in response to meals and its primary function is to facilitate 
utilization of glucose in the body. Hence, in people with diabetes type 2, body fails to utilize glucose 
despite presence of insulin. At this stage the treatment generally consists of oral administration of 
antidiabetic drugs. With progression of disease, patients also develop insulin deficiency and treatment 
now often requires administration of insulin.  
Another type of diabetes that generally affects children and adolescents results from inability of the 
pancreas to produce insulin and there is absolute insulin deficiency. This inability of the pancreas is due 
to loss of specific cell, known as the beta cells of pancreas. In majority of cases, destruction of beta cells 
results from body’s abnormal immune response towards beta cells. The causes of abnormal immune 
responses are not yet entirely understood, however, scientists believe that both the genetic and 
environmental factors are important triggers. Its onset has nothing to do with diet or lifestyle and as there 
is absolute deficiency of insulin, the only treatment is insulin injections for the lifetime.  
Both type 1 and type 2 diabetes are associated with dangerous and debilitating complications. In a 
multinational study, 50% of people with diabetes die of cardiovascular disease, primarily heart disease 
and stroke (Morrish et al. 2001). Several other complications of diabetes include damage to kidneys, 
nerves and retina. Living with diabetes, particularly diabetes type 1 is a constant challenge. Patients must 
carefully balance insulin doses with eating and other activities throughout the day and night. They must 
also measure blood-glucose level by pricking their fingers few times a day. Despite all precautionary 
measures, people with type 1 diabetes still run the risk of dangerously high or low blood-glucose levels, 
both of which can be life threatening. 
Regenerative medicine in diabetes 
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Although, insulin injections help patient with diabetes to survive, the root cause of the disease still 
persists. Hence, regeneration of pancreatic beta cells is the answer for definitive treatment of insulin-
dependent diabetics. The purpose of regenerating beta cells is to restore the number of pancreatic beta 
cells to regain the body’s original ability to regulate blood glucose levels. Hence, regenerative 
technologies in medicine are now offering solutions and hope to people who are suffering from conditions 
due to irreparable damage to tissues and organs.  
There are two commonly investigated methods for regenerating lost beta cells of pancreas. In one method 
beta cells are first prepared in laboratory and then are implanted in the patient’s body (Ex vivo approach). 
Another method aims to regenerate beta cells in the body by introducing genes and some factors that help 
in regenerating beta cells (In vivo approach). 
Ex vivo approach 
Ex vivo approach uses stem cells for regenerating beta cells of pancreas. Stem cells can be considered the 
mother cells that are capable of self-renewing as well as multiplying and developing into any other type 
of cell such as those of blood, heart, bones, skin, muscles, brain etc. Because of their ability to replenish 
other cell types, they act as an internal repair system. Stem cells by themselves are unspecialized cells i.e. 
they cannot perform any specialized function of the body until they transform and specialize into other 
cell types. The process by which unspecialized stem cells become specialized cells is known as 
differentiation and it occurs in several steps. What triggers the cell differentiation still remains 
incompletely understood. Scientists believe that internal triggers that reside within the gene could have a 
role to play. At the same time there can be external factors such as chemicals secreted by other cells, 
contact with neighboring cells or some molecules in the microenvironment of these cells. Answers to 
several questions regarding differentiation remain unknown. For example: which is the stronger trigger- 
genes or the external factors; do all cells differentiate in response to similar triggers; are there any specific 
factors that trigger differentiation of stem cells into specific specialized cells? Answers to these questions 
would greatly benefit development of stem cell based therapies for specific diseases. 
There are different sources of stem cells and accordingly stem cells can be of 3 different types: 
Embryonic stem cells: These stem cells, as the name suggests, are derived from embryos. Scientists were 
first able to obtain stem cells from mouse embryo in 1981. Further studies on these cells led to discovery 
of methods to derive stem cells from human embryo in 1998. Embryonic stem cells are derived from 
embryos that develop from a fertilized egg in an in vitro fertilization clinic and then donated for use in 
research with informed consent of the donor. They are not obtained from the fertilized eggs in a woman’s 
body. The cells from human embryo are grown or cultured in a plastic laboratory dish containing a 
nutrient broth, known as culture media. Once the cells survive and multiply, they can be sub-cultured into 
several fresh dishes. Embryonic stem cells that have proliferated in culture for a long time without 
differentiating, and are capable of differentiating into specialized cells are referred to as an embryonic 
stem cell line. Scientists expose these undifferentiated stem cells in culture to specific triggers to allow 
there differentiation into specific cell types such as insulin secreting beta cells. 
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Adult stem cells: These are found in the adult tissues or organs. They can renew themselves and may 
differentiate into all of the major specialized cell types of the tissue or organ. Their primary roles in a 
living organism are to maintain and repair the tissue in which they are found. The most commonly used 
example is the bone marrow. Research is ongoing to find optimal methods that can allow rapid growth of 
adult stem cells in laboratory and also the recipes to direct their differentiation into specific cell type. As 
compared to embryonic stem cells, adult stem cells can differentiate only into the different cell types of 
their tissue of origin. Since the adult stem cells are very few in a mature organ, it is difficult to find them 
and they are also difficult to grow compared to embryonic cells. 
 Induced pluripotent stem cells: These are the adult cells that have been genetically reprogrammed to an 
embryonic stem cell–like state. They behave like embryonic stem cells and features that differentiate 
them from embryonic cells are not fully known. 
There are several reports of using all three types of stem cells, especially in animals, to regenerate beta 
cells that can produce insulin (Hori et al. 2002; Lumelsky et al. 2001; Nir et al. 2007; Takahashi et al. 
2007). However, it still remains difficult to accurately direct differentiation of any of these cell types and 
produce mass quantities of insulin producing beta cells. Furthermore, their effectiveness and possible 
adverse effects in patients remain to be determined. 
In vivo approach 
In vivo approach is based on creating insulin secreting beta cells by manipulating cells that exist in the 
body. The technique uses genes that produce differentiating factors. These differentiating factors target 
adult stem cells that exist in liver and are of pancreatic beta cell lineage i.e. they can differentiate into 
insulin secreting beta cells. Hence, the in vivo approach uses adult stem cells that exist in the body and 
hence is considered more physiological. There is no requirement for transplanting the cells or tissue and 
hence the method is noninvasive. Ethical issues are also not a big concern with this technique as is the 
case with the in vitro approach. However, there are several unresolved issues such as control of in vivo 
differentiation and safety and efficacy of these methods.  
This approach seems to be particularly useful in patients with diabetes mellitus type 2 who have not lost 
the beta cell mass completely. Scientists have shown that pancreatic beta cells retain the self-propagating 
properties and can be triggered to proliferate by differentiating factors. Some studies have shown that 
GLP-1, a hormone from gut, stimulates proliferation of beta cells (Xu et al. 1999; Brubaker et al. 2004). 
There are also reports suggesting methods that employ introduction of genes into cells of completely 
different lineage and stimulate them to develop into insulin secreting cells. This approach may be useful 
in patients with diabetes mellitus type 1 who have completely lost the pancreatic beta cells.  
2.0 CONCLUSIONS   
Management of diabetes and its long-term complications remains a challenge for physicians and patients. 
Regenerative medicine that aims to re-establish the insulin secreting mass of beta cells of pancreas 
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provides great hopes as a new treatment modality. Current status in this field is rapidly developing; 
however, several technological details are yet to be explored. Moreover, further scientific investigation 
into the disease etiology, diagnostic tools for early detection and monitoring are also crucial. Perhaps the 
integrated approach involving several research fields is the key in making regenerative medicine achieve 
its purpose of completely curing diabetes mellitus.  
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